ILF2:恶性瘤中的多方面调节剂及其作为生物标志物和治疗点的前景
Tonglin Sun1,2, Xi Li3, Yi Zhang4
1Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Frontiers in oncology
|December 30, 2024
概括
干白素增强剂结合因子2 (ILF2),也称为核因子45 (NF45),在许多癌症中被上调. 这种蛋白质促进瘤生长,可以作为诊断和预后生物标志物.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 基因规则 基因规则
背景情况:
- 介素增强剂结合因子2 (ILF2),以前称为核因子45 (NF45),是一种广泛存在于人体组织中的蛋白质.
- ILF2与ILF3相互作用,调节DNA和RNA代谢中的基因表达.
- 在各种癌症中观察到ILF2表达的升高,包括食道,肺和胃恶性瘤.
研究的目的:
- 审查ILF2在恶性瘤的发展和进展中的作用和机制.
- 探索ILF2作为癌症早期诊断和预后的生物标志物的潜力.
主要方法:
- 最近关于ILF2在癌症中的研究的文献综述.
- 分析ILF2在瘤发育,增殖,细胞循环和上皮-介质细胞转变 (EMT) 的参与.
- 检查ILF2与瘤细胞迁移,入侵,血管生成和患者结果的相关性.
主要成果:
- 上调ILF2与增强瘤发育和扩散有关.
- ILF2影响细胞循环的进展,并诱导EMT.
- ILF2表达与瘤细胞迁移,入侵和新血管生成的增加相关.
结论:
- ILF2在促进恶性瘤进展方面发挥着重要作用.
- ILF2是早期癌症诊断和预后评估的潜在生物标志物.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy
394
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
394
lncRNA - Long Non-coding RNAs
8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K


